The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
News|Videos|September 30, 2026 (Updated: September 30, 2026)
First-Line Amivantamab-chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival From PAPILLON
Author(s)Chul Kim, MD
The Phase 3 PAPILLON study evaluated first-line amivantamab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations. The amivantamab-chemotherapy group achieved the longest median overall survival reported to date in this population compared to chemotherapy alone. After adjusting for the high rate of crossover to second-line amivantamab among patients initially assigned to chemotherapy, the combination treatment demonstrated a statistically significant overall survival benefit.
Advertisement
The Phase 3 PAPILLON study evaluated first-line amivantamab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations. The amivantamab-chemotherapy group achieved the longest median overall survival reported to date in this population compared to chemotherapy alone. After adjusting for the high rate of crossover to second-line amivantamab among patients initially assigned to chemotherapy, the combination treatment demonstrated a statistically significant overall survival benefit.
Advertisement
Related to this article
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
2
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Dr Pelster on the MAPKeeper 301 Trial Evaluating Atebimetinib in First-Line Metastatic Pancreatic Cancer
5